With the PACIFIC trial, which compared a PD-L1 inhibitor, durvalumab, to observation after chemoradiation in Stage III lung cancer patients, showing significantly improved progression-free and overall survival outcomes [21], we expect that this population will increase tremendously in the near future. The gene discussed is CD274; the disease is lung carcinoma.